Clinical Trial: A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Thr
Brief Summary: The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
Detailed Summary:
Sponsor: Lux Biosciences, Inc.
Current Primary Outcome: anterior chamber cells [ Time Frame: 16 and 24 weeks ]
Original Primary Outcome:
Current Secondary Outcome:
- BCVA [ Time Frame: 24 weeks ]
- macular thickness [ Time Frame: 16 and 24 weeks ]
Original Secondary Outcome:
Information By: Lux Biosciences, Inc.
Dates:
Date Received: November 27, 2006
Date Started: January 2007
Date Completion:
Last Updated: June 21, 2012
Last Verified: June 2012